1.98
+0.01(+0.51%)
Currency In USD
| Previous Close | 1.97 |
| Open | 1.99 |
| Day High | 1.99 |
| Day Low | 1.98 |
| 52-Week High | 21.92 |
| 52-Week Low | 1.17 |
| Volume | 45,945 |
| Average Volume | 263,545 |
| Market Cap | 11.99M |
| PE | -0.18 |
| EPS | -11.12 |
| Moving Average 50 Days | 1.63 |
| Moving Average 200 Days | 4.94 |
| Change | 0.01 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $11.22 as of July 02, 2025 at a share price of $1.98. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $2.37 as of July 02, 2025 at a share price of $1.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to d
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
May 27, 2025 12:01 PM GMT
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to d
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
GlobeNewswire Inc.
May 27, 2025 11:00 AM GMT
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearing